

# James P Allison

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1907143/publications.pdf>

Version: 2024-02-01

275  
papers

83,684  
citations

558

126  
h-index

460

272  
g-index

283  
all docs

283  
docs citations

283  
times ranked

65119  
citing authors

#	ARTICLE	IF	CITATIONS
1	The future of immune checkpoint therapy. <i>Science</i> , 2015, 348, 56-61.	12.6	3,735
2	Restoring function in exhausted CD8 T cells during chronic viral infection. <i>Nature</i> , 2006, 439, 682-687.	27.8	3,471
3	Enhancement of Antitumor Immunity by CTLA-4 Blockade. <i>Science</i> , 1996, 271, 1734-1736.	12.6	3,231
4	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	12.6	3,126
5	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2018, 8, 1069-1086.	9.4	2,128
6	CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.. <i>Journal of Experimental Medicine</i> , 1995, 182, 459-465.	8.5	1,922
7	Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. <i>Cancer Cell</i> , 2014, 25, 719-734.	16.8	1,892
8	Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. <i>Cell</i> , 2015, 161, 205-214.	28.9	1,872
9	Immunologic Correlates of the Abскоп Effect in a Patient with Melanoma. <i>New England Journal of Medicine</i> , 2012, 366, 925-931.	27.0	1,836
10	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature</i> , 2014, 515, 577-581.	27.8	1,705
11	PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 4275-4280.	7.1	1,602
12	CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. <i>Nature</i> , 1992, 356, 607-609.	27.8	1,516
13	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8372-8377.	7.1	1,482
14	Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. <i>Journal of Experimental Medicine</i> , 2013, 210, 1695-1710.	8.5	1,203
15	The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research. <i>Clinical Cancer Research</i> , 2009, 15, 5323-5337.	7.0	1,177
16	Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. <i>Nature</i> , 2012, 482, 400-404.	27.8	1,075
17	Loss of IFN- $\gamma$ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. <i>Cell</i> , 2016, 167, 397-404.e9.	28.9	1,009
18	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. <i>Cell</i> , 2017, 170, 1120-1133.e17.	28.9	960

#	ARTICLE	IF	CITATIONS
19	Synergism of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses. <i>Journal of Experimental Medicine</i> , 2001, 194, 823-832.	8.5	959
20	Combination Immunotherapy of B16 Melanoma Using Anti-“Cytotoxic T Lymphocyte-Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation. <i>Journal of Experimental Medicine</i> , 1999, 190, 355-366.	8.5	951
21	Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 4712-4717.	7.1	940
22	CTLA-4-MEDIATED INHIBITION IN REGULATION OF CELL RESPONSES: Mechanisms and Manipulation in Tumor Immunotherapy. <i>Annual Review of Immunology</i> , 2001, 19, 565-594.	21.8	905
23	CTLA-4: new insights into its biological function and use in tumor immunotherapy. <i>Nature Immunology</i> , 2002, 3, 611-618.	14.5	843
24	ICOS co-stimulatory receptor is essential for T-cell activation and function. <i>Nature</i> , 2001, 409, 97-101.	27.8	840
25	CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. <i>Journal of Experimental Medicine</i> , 1996, 183, 2533-2540.	8.5	837
26	Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-“CTLA-4 antibodies. <i>Journal of Experimental Medicine</i> , 2009, 206, 1717-1725.	8.5	785
27	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	9.4	785
28	BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. <i>Nature Immunology</i> , 2003, 4, 670-679.	14.5	768
29	Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. <i>Nature Medicine</i> , 2015, 21, 998-1009.	30.7	736
30	Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. <i>Journal of Experimental Medicine</i> , 2010, 207, 637-650.	8.5	715
31	Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. <i>Cancer Discovery</i> , 2015, 5, 860-877.	9.4	696
32	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	689
33	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012, 10, 205.	4.4	676
34	Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. <i>Clinical Cancer Research</i> , 2005, 11, 728-34.	7.0	662
35	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. <i>Nature Communications</i> , 2016, 7, 12632.	12.8	648
36	CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. <i>Journal of Clinical Investigation</i> , 2006, 116, 1935-1945.	8.2	605

#	ARTICLE	IF	CITATIONS
37	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3005-3010.	7.1	604
38	Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy. Science Translational Medicine, 2014, 6, 226ra32.	12.4	590
39	The Emerging Role of CTLA-4 as an Immune Attenuator. Immunity, 1997, 7, 445-450.	14.3	582
40	Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. Journal of Experimental Medicine, 2013, 210, 1389-1402.	8.5	562
41	Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nature Reviews Cancer, 2011, 11, 805-812.	28.4	554
42	PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5336-5341.	7.1	536
43	Limited diversity of $\beta_2\text{-microglobulin}$ antigen receptor genes of thy-1+ dendritic epidermal cells. Cell, 1988, 55, 837-847.	28.9	523
44	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature Medicine, 2018, 24, 1804-1808.	30.7	521
45	Checkpoint Blockade in Cancer Immunotherapy. Advances in Immunology, 2006, 90, 297-339.	2.2	498
46	Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine, 2011, 17, 1094-1100.	30.7	476
47	VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 2017, 23, 551-555.	30.7	467
48	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	3.8	459
49	Immune Modulation in Cancer with Antibodies. Annual Review of Medicine, 2014, 65, 185-202.	12.2	455
50	Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength. Immunity, 2002, 16, 23-35.	14.3	452
51	Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nature Communications, 2017, 8, 15095.	12.8	432
52	Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Current Opinion in Immunology, 2006, 18, 206-213.	5.5	426
53	Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting. Cancer, 2010, 116, 1767-1775.	4.1	405
54	Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Clinical Cancer Research, 2010, 16, 2861-2871.	7.0	404

#	ARTICLE	IF	CITATIONS
55	Co-stimulation in T cell responses. <i>Current Opinion in Immunology</i> , 1997, 9, 396-404.	5.5	401
56	B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse. <i>Immunity</i> , 2004, 21, 401-413.	14.3	390
57	Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. <i>Cell Reports</i> , 2015, 13, 412-424.	6.4	387
58	A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1810-1815.	7.0	385
59	Lymphoproliferation in CTLA-4 Deficient Mice Is Mediated by Costimulation-Dependent Activation of CD4 + T Cells. <i>Immunity</i> , 1997, 7, 885-895.	14.3	384
60	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. <i>Cancer Discovery</i> , 2019, 9, 370-383.	9.4	380
61	Epitope Landscape in Breast and Colorectal Cancer. <i>Cancer Research</i> , 2008, 68, 889-892.	0.9	373
62	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	12.6	369
63	Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 8099-8103.	7.1	364
64	The Next Decade of Immune Checkpoint Therapy. <i>Cancer Discovery</i> , 2021, 11, 838-857.	9.4	363
65	B7x: A widely expressed B7 family member that inhibits T cell activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 10388-10392.	7.1	362
66	Costimulatory regulation of T cell function. <i>Current Opinion in Cell Biology</i> , 1999, 11, 203-210.	5.4	359
67	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021, 27, 504-514.	30.7	357
68	CTLA-4 blockade synergizes with tumor-derived granulocyte macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 10067-10071.	7.1	356
69	B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19458-19463.	7.1	336
70	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 20410-20415.	7.1	322
71	Integrated NY-ESO-1 antibody and CD8 <sup>+</sup> T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 16723-16728.	7.1	310
72	The B7 Family and Cancer Therapy: Costimulation and Coinhibition. <i>Clinical Cancer Research</i> , 2007, 13, 5271-5279.	7.0	308

#	ARTICLE	IF	CITATIONS
73	Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine. <i>Journal of Experimental Medicine</i> , 2001, 194, 481-490.	8.5	307
74	Origin of Thy-1+ dendritic epidermal cells of adult mice from fetal thymic precursors. <i>Nature</i> , 1990, 344, 68-70.	27.8	299
75	CD28-B7 interactions in T-cell activation. <i>Current Opinion in Immunology</i> , 1994, 6, 414-419.	5.5	298
76	Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function. <i>Clinical Cancer Research</i> , 2007, 13, 2158-2167.	7.0	293
77	Aire-Dependent Thymic Development of Tumor-Associated Regulatory T Cells. <i>Science</i> , 2013, 339, 1219-1224.	12.6	282
78	Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes. <i>Journal of Experimental Medicine</i> , 1998, 187, 427-432.	8.5	277
79	Dissecting the mechanisms of immune checkpoint therapy. <i>Nature Reviews Immunology</i> , 2020, 20, 75-76.	22.7	275
80	Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. <i>Annals of the New York Academy of Sciences</i> , 2013, 1291, 1-13.	3.8	270
81	Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?. <i>Cancer Immunology Research</i> , 2014, 2, 831-838.	3.4	270
82	Expression of Helios in Peripherally Induced Foxp3+ Regulatory T Cells. <i>Journal of Immunology</i> , 2012, 188, 976-980.	0.8	268
83	CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help.. <i>Journal of Experimental Medicine</i> , 1993, 177, 1791-1796.	8.5	265
84	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 1233-1238.	7.0	260
85	Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti-CTLA-4 Therapy. <i>Cancer Research</i> , 2012, 72, 430-439.	0.9	248
86	TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. <i>Journal of Experimental Medicine</i> , 2010, 207, 1701-1711.	8.5	244
87	Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. <i>Journal of Experimental Medicine</i> , 2014, 211, 715-725.	8.5	242
88	Structure, Function, and Serology of the T-Cell Antigen Receptor Complex. <i>Annual Review of Immunology</i> , 1987, 5, 503-540.	21.8	240
89	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. <i>Nature Medicine</i> , 2020, 26, 39-46.	30.7	236
90	Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation. <i>Journal of Immunology</i> , 2004, 173, 6098-6108.	0.8	234

#	ARTICLE	IF	CITATIONS
91	Alternative Activation Is an Innate Response to Injury That Requires CD4+ T Cells to be Sustained during Chronic Infection. <i>Journal of Immunology</i> , 2007, 179, 3926-3936.	0.8	230
92	Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. <i>Immunological Reviews</i> , 2011, 241, 104-118.	6.0	229
93	Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22699-22709.	7.1	226
94	The mouse T cell receptor: Structural heterogeneity of molecules of normal T cells defined by Xenoantiserum. <i>Cell</i> , 1983, 34, 739-746.	28.9	220
95	CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. <i>Blood</i> , 2008, 112, 1175-1183.	1.4	217
96	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	30.7	216
97	Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 15074-15079.	7.1	214
98	Anti-CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy. <i>Seminars in Oncology</i> , 2010, 37, 473-484.	2.2	208
99	Cell intrinsic mechanisms of T cell inhibition and application to cancer therapy. <i>Immunological Reviews</i> , 2008, 224, 141-165.	6.0	207
100	Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. <i>Modern Pathology</i> , 2010, 23, 1104-1112.	5.5	204
101	Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11919-11924.	7.1	197
102	Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). <i>Current Opinion in Immunology</i> , 2010, 22, 326-332.	5.5	195
103	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. <i>Cancer Research</i> , 2017, 77, 839-850.	0.9	195
104	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , 2020, 26, 1845-1851.	30.7	193
105	Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production. <i>PLoS ONE</i> , 2011, 6, e19499.	2.5	189
106	Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. <i>Journal of Experimental Medicine</i> , 2008, 205, 2125-2138.	8.5	185
107	T Cell Immunoglobulin Mucin-3 Crystal Structure Reveals a Galectin-9-Independent Ligand-Binding Surface. <i>Immunity</i> , 2007, 26, 311-321.	14.3	183
108	Strength of TCR-Peptide/MHC Interactions and In Vivo T Cell Responses. <i>Journal of Immunology</i> , 2011, 186, 5039-5045.	0.8	182

#	ARTICLE	IF	CITATIONS
109	Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy. <i>Cancer Immunology Research</i> , 2013, 1, 229-234.	3.4	178
110	Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 9273-9278.	7.1	175
111	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. <i>Clinical Cancer Research</i> , 2016, 22, 5729-5737.	7.0	175
112	The Yin and Yang of T Cell Costimulation. <i>Science</i> , 1995, 270, 932-932.	12.6	172
113	Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 3813-3818.	8.2	169
114	The T cell antigen receptor complex expressed on normal peripheral blood CD4+, CD8+ T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer. <i>Journal of Experimental Medicine</i> , 1987, 165, 1076-1094.	8.5	168
115	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017, 7, 1088-1097.	9.4	160
116	Manipulation of costimulatory signals to enhance antitumor T-cell responses. <i>Current Opinion in Immunology</i> , 1995, 7, 682-686.	5.5	158
117	Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. <i>Journal of Experimental Medicine</i> , 2013, 210, 743-755.	8.5	157
118	In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 11476-11481.	7.1	155
119	Single dose of anti-CTLA-4 enhances CD8 <sup>+</sup> T-cell memory formation, function, and maintenance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 266-271.	7.1	151
120	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers Response. <i>Clinical Cancer Research</i> , 2019, 25, 3469-3470.	7.0	151
121	Negative regulators of T cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. <i>Immunological Reviews</i> , 2009, 229, 67-87.	6.0	150
122	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. <i>Cancer Discovery</i> , 2021, 11, 614-625.	9.4	145
123	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015, 25, 208-224.	12.0	143
124	Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22246-22251.	7.1	142
125	Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , 2020, 11, 603.	12.8	140
126	Defining the critical hurdles in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2011, 9, 214.	4.4	139

#	ARTICLE	IF	CITATIONS
127	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. <i>Cancer Immunology Research</i> , 2016, 4, 835-844.	3.4	138
128	Thymocyte development is normal in CTLA-4-deficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 9296-9301.	7.1	137
129	Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. <i>JCI Insight</i> , 2020, 5, .	5.0	130
130	Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. <i>International Immunology</i> , 1996, 8, 519-523.	4.0	128
131	Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. <i>Clinical and Experimental Immunology</i> , 2009, 157, 9-19.	2.6	126
132	Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors. <i>Cancer Research</i> , 2009, 69, 7747-7755.	0.9	120
133	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	120
134	Murine Ia and human DR antigens: homology of amino-terminal sequences.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1978, 75, 3953-3956.	7.1	119
135	Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4+ T cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 8603-8608.	7.1	119
136	B7 Expression on T Cells Down-Regulates Immune Responses through CTLA-4 Ligation via R-T Interactions. <i>Journal of Immunology</i> , 2004, 172, 34-39.	0.8	118
137	Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals. <i>Clinical Cancer Research</i> , 2010, 16, 2781-2791.	7.0	118
138	CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. <i>Vaccine</i> , 2004, 22, 1700-1708.	3.8	116
139	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	16.8	115
140	CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism. <i>Journal of Immunology</i> , 2006, 177, 1052-1061.	0.8	112
141	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. <i>Nature Communications</i> , 2017, 8, 14340.	12.8	110
142	T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF- $\beta$ 1 Cytokine. <i>Immunity</i> , 2011, 35, 123-134.	14.3	109
143	Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients. <i>Cancer Immunology Research</i> , 2013, 1, 235-244.	3.4	109
144	Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	108

#	ARTICLE	IF	CITATIONS
145	HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. <i>Nature Communications</i> , 2017, 8, 451.	12.8	107
146	Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 <sup>+</sup> T Lymphocytes. <i>Science</i> , 2008, 319, 215-220.	12.6	103
147	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2018, 6, 189-200.	3.4	102
148	Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. <i>Journal of Neuroimmunology</i> , 1997, 73, 57-62.	2.3	99
149	Attenuated T Cell Responses to a High-Potency Ligand In Vivo. <i>PLoS Biology</i> , 2010, 8, e1000481.	5.6	99
150	Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17765-17770.	7.1	97
151	Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 6187-6192.	7.1	97
152	Engagement of NKG2D by Cognate Ligand or Antibody Alone Is Insufficient to Mediate Costimulation of Human and Mouse CD8 <sup>+</sup> T Cells. <i>Journal of Immunology</i> , 2005, 174, 1922-1931.	0.8	96
153	Activation and differentiation requirements of primary T cells in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 8987-8991.	7.1	95
154	Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 12204-12209.	7.1	95
155	Cutting Edge: CTLA-4 on Effector T Cells Inhibits In <i>Trans</i> . <i>Journal of Immunology</i> , 2012, 189, 1123-1127.	0.8	94
156	Interdependent IL-7 and IFN- $\gamma$ signalling in T-cell controls tumour eradication by combined $\pm$ -CTLA-4+ $\pm$ -PD-1 therapy. <i>Nature Communications</i> , 2016, 7, 12335.	12.8	93
157	Repression of B7.2 on Self-reactive B Cells Is Essential to Prevent Proliferation and Allow Fas-mediated Deletion by CD4 <sup>+</sup> T Cells. <i>Journal of Experimental Medicine</i> , 1998, 188, 651-659.	8.5	89
158	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. <i>Cancer Immunology Research</i> , 2019, 7, 1903-1909.	3.4	86
159	Identification of antigen receptor-associated structures on murine T cells. <i>Nature</i> , 1985, 314, 107-109.	27.8	85
160	Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 881-886.	7.1	84
161	Strategies for combining immunotherapy with radiation for anticancer therapy. <i>Immunotherapy</i> , 2015, 7, 967-980.	2.0	83
162	CTLA-4 blockade increases antigen-specific CD8 <sup>+</sup> T cells in prevaccinated patients with melanoma: three cases. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1137-1146.	4.2	82

#	ARTICLE	IF	CITATIONS
163	<i>ARID1A</i> mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	82
164	Unique potential of 4-1BB agonist antibody to promote durable regression of HPV <sup>+</sup> tumors when combined with an E6/E7 peptide vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E5290-9.	7.1	79
165	CD28 disruption exacerbates inflammation in Tgf- $\hat{1}^21$ -/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF- $\hat{1}^21$ . <i>Blood</i> , 2004, 103, 4594-4601.	1.4	75
166	Immune Checkpoint Blockade in Cancer Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1113.	7.4	75
167	Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. <i>Immunity</i> , 2019, 50, 1084-1098.e10.	14.3	75
168	Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced Stage. <i>Cancer Research</i> , 2008, 68, 6054-6058.	0.9	71
169	Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3013-3017.	7.1	69
170	Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific T-cell Motility. <i>Cancer Immunology Research</i> , 2014, 2, 970-980.	3.4	68
171	A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukemia cell binding of its cognate retrovirus. <i>Cell</i> , 1987, 49, 143-151.	28.9	66
172	Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein. <i>Clinical Cancer Research</i> , 2013, 19, 6112-6125.	7.0	66
173	Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative. <i>Cancer Cell</i> , 2007, 12, 192-199.	16.8	65
174	Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 12711-12716.	7.1	64
175	Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. <i>Journal of Hematology and Oncology</i> , 2016, 9, 81.	17.0	62
176	The role of short homology repeats and TdT in generation of the invariant $\hat{1}^3\hat{1}$ antigen receptor repertoire in the fetal thymus. <i>Immunity</i> , 1995, 3, 439-447.	14.3	61
177	Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2021, 27, 4557-4565.	7.0	61
178	The T-cell antigen receptor gamma gene: rearrangement and cell lineages. <i>Trends in Immunology</i> , 1987, 8, 293-296.	7.5	60
179	T cell receptor-triggered activation of intraepithelial lymphocytes in vitro. <i>International Immunology</i> , 1993, 5, 145-153.	4.0	59
180	Insolubilization of L-asparaginase by covalent attachment to nylon tubing. <i>Biochemical and Biophysical Research Communications</i> , 1972, 47, 66-73.	2.1	58

#	ARTICLE	IF	CITATIONS
181	The Role of B7 Costimulation in CD4/CD8 T Cell Homeostasis. <i>Journal of Immunology</i> , 2000, 164, 3543-3553.	0.8	56
182	Identification of dipeptidyl peptidase IV as a protein shared by the plasma membrane of hepatocytes and liver biomatrix. <i>Experimental Cell Research</i> , 1985, 158, 509-518.	2.6	55
183	Î³Î³ T-cell development. <i>Current Opinion in Immunology</i> , 1993, 5, 241-246.	5.5	55
184	B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. <i>Blood</i> , 2015, 125, 3335-3346.	1.4	55
185	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncolmunology</i> , 2016, 5, e1136044.	4.6	55
186	Cutting Edge: A Crucial Role for B7-CD28 in Transmitting T Help from APC to CTL. <i>Journal of Immunology</i> , 2002, 169, 4094-4097.	0.8	54
187	Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1263-1270.	4.2	54
188	Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. <i>Journal of Experimental Medicine</i> , 2011, 208, 1683-1694.	8.5	54
189	Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. <i>Cancer Immunology Research</i> , 2019, 7, 1390-1395.	3.4	54
190	TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10453-10462.	7.1	53
191	LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	53
192	Lack of a role for transforming growth factor-Î in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 2587-2592.	7.1	50
193	Regulated Costimulation in the Thymus Is Critical for T Cell Development: Dysregulated CD28 Costimulation Can Bypass the Pre-TCR Checkpoint. <i>Journal of Immunology</i> , 2005, 175, 4199-4207.	0.8	50
194	Itk Negatively Regulates Induction of Î T Cell Proliferation by CD28 Costimulation. <i>Journal of Experimental Medicine</i> , 1997, 186, 221-228.	8.5	48
195	Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 3106-3111.	1.5	47
196	ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection. <i>Cancer Research</i> , 2016, 76, 3684-3689.	0.9	47
197	Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. <i>British Journal of Haematology</i> , 2005, 130, 809-824.	2.5	46
198	SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3509-3514.	7.1	46

#	ARTICLE	IF	CITATIONS
199	Augmented IL-15 <sup>R</sup> Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice. <i>Journal of Immunology</i> , 2012, 188, 6156-6164.	0.8	46
200	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 100-105.	3.4	46
201	Intrathymic differentiation of V gamma 3 T cells.. <i>Journal of Experimental Medicine</i> , 1993, 178, 309-315.	8.5	45
202	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. <i>Nature Communications</i> , 2021, 12, 6071.	12.8	44
203	T Cell-Mediated Elimination of B7.2 Transgenic B Cells. <i>Immunity</i> , 1997, 6, 327-339.	14.3	43
204	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 5045.	12.8	42
205	Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 442-447.	1.6	40
206	Friends Not Foes: CTLA-4 Blockade and mTOR Inhibition Cooperate during CD8+ T Cell Priming To Promote Memory Formation and Metabolic Readiness. <i>Journal of Immunology</i> , 2015, 194, 2089-2098.	0.8	39
207	Frontiers in cancer immunotherapy—a symposium report. <i>Annals of the New York Academy of Sciences</i> , 2021, 1489, 30-47.	3.8	39
208	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. <i>Blood</i> , 2019, 134, 830-830.	1.4	38
209	Characterization and Comparison of GITR Expression in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6501-6510.	7.0	37
210	[55] HLA antigens in serum. <i>Methods in Enzymology</i> , 1984, 108, 614-624.	1.0	36
211	Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. <i>Cytotherapy</i> , 2009, 11, 912-922.	0.7	35
212	Gene Therapy-Mediated Reprogramming Tumor Infiltrating T Cells Using IL-2 and Inhibiting NF- $\kappa$ B Signaling Improves the Efficacy of Immunotherapy in a Brain Cancer Model. <i>Neurotherapeutics</i> , 2012, 9, 827-843.	4.4	33
213	CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. <i>Oncolmmunology</i> , 2012, 1, 544-546.	4.6	32
214	Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 849-854.	3.4	32
215	Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. <i>Clinical Cancer Research</i> , 2018, 24, 1011-1018.	7.0	31
216	Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. <i>Cancer Immunology Research</i> , 2019, 7, 1803-1812.	3.4	31

#	ARTICLE	IF	CITATIONS
217	Hâ€“2 Antigens on a murine lymphoma are associated with additional proteins. <i>Nature</i> , 1978, 271, 165-167.	27.8	30
218	Vaccination with tumor cells expressing IL-15 and IL-15RÎ± inhibits murine breast and prostate cancer. <i>Gene Therapy</i> , 2014, 21, 393-401.	4.5	30
219	Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. , 2021, 9, e002919.		30
220	Biosynthesis and processing of murine T-cell antigen receptor. <i>Cell</i> , 1984, 38, 659-665.	28.9	29
221	Antibodies against the T cell receptor/CD3 complex interfere with distinct intra-thymic cell-cell interactions in vivo: correlation with arrest of T cell differentiation. <i>European Journal of Immunology</i> , 1989, 19, 857-863.	2.9	29
222	Immunotherapeutic Strategies for High-Risk Bladder Cancer. <i>Seminars in Oncology</i> , 2007, 34, 165-172.	2.2	29
223	B7x in the Periphery Abrogates Pancreas-Specific Damage Mediated by Self-reactive CD8 T Cells. <i>Journal of Immunology</i> , 2012, 189, 4165-4174.	0.8	29
224	De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. <i>Cancer Immunology Research</i> , 2016, 4, 279-288.	3.4	29
225	A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. <i>Science Translational Medicine</i> , 2022, 14, eabm6420.	12.4	29
226	A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation. <i>Blood</i> , 2018, 132, 296-296.	1.4	27
227	The Murine T Cell Antigen Receptor and Associated Structures. <i>Immunological Reviews</i> , 1984, 81, 145-160.	6.0	26
228	Cell surface expression by adult rat hepatocytes of a non-collagen glycoprotein present in rat liver biomatrix. <i>Experimental Cell Research</i> , 1984, 152, 402-414.	2.6	25
229	Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulinitis and destruction of Î² cells. <i>Blood</i> , 2007, 110, 954-961.	1.4	25
230	The role of tyrosine phosphorylation and PTP-1C in CTLA-4 signal transduction. <i>European Journal of Immunology</i> , 1996, 26, 3224-3229.	2.9	24
231	The gamma T-cell antigen receptor. <i>Journal of Clinical Immunology</i> , 1987, 7, 429-440.	3.8	23
232	Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. <i>Arthritis Research</i> , 2004, 6, 208.	2.0	23
233	Checkpoints. <i>Cell</i> , 2015, 162, 1202-1205.	28.9	23
234	Phenotypic and functional analysis of positive selection in the gamma/delta T cell lineage.. <i>Journal of Experimental Medicine</i> , 1993, 177, 1061-1070.	8.5	21

#	ARTICLE	IF	CITATIONS
235	Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 9872-9877.	7.1	21
236	First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRRC15, in Sarcomas and Other Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3556-3566.	7.0	21
237	Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 905-905.	1.4	21
238	Chemical and immunological characterization of developmentally expressed chicken erythroid surface membrane antigens. <i>Developmental Biology</i> , 1982, 91, 389-396.	2.0	20
239	Expression of a fetal $\beta 2 T$ -cell receptor in adult mice triggers a non-MHC-linked form of selective depletion. <i>International Immunology</i> , 1991, 3, 385-393.	4.0	20
240	To be or not to be B7. <i>Journal of Clinical Investigation</i> , 2006, 116, 2590-2593.	8.2	20
241	Co-stimulation via CD28 induces activation of a refractory subset of MRL-lpr/lpr T lymphocytes. <i>International Immunology</i> , 1993, 5, 1451-1460.	4.0	15
242	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. <i>Nature Communications</i> , 2020, 11, 1839.	12.8	15
243	The substrate specificity of L-asparaginase from <i>Alcaligenes eutrophus</i> . <i>FEBS Letters</i> , 1971, 14, 107-108.	2.8	14
244	Cytotoxic T Lymphocyte Antigen 4 (CD152) Regulates Self-Reactive T cells in BALB/c but not in the Autoimmune NOD Mouse. <i>Journal of Autoimmunity</i> , 2000, 14, 123-131.	6.5	14
245	Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. <i>Blood</i> , 2018, 132, 906-906.	1.4	13
246	A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. <i>Genomics</i> , 2006, 88, 841-845.	2.9	12
247	Prostate Cancer. <i>BioDrugs</i> , 2003, 17, 131-138.	4.6	11
248	The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor. <i>Blood</i> , 2002, 99, 4509-4516.	1.4	10
249	Inhibitors of B7-CD28 costimulation in urologic malignancies. <i>Immunotherapy</i> , 2009, 1, 129-139.	2.0	10
250	Response to ipilimumab (Yervoy) and the TGN1412 catastrophe. <i>Immunobiology</i> , 2012, 217, 590-592.	1.9	10
251	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. <i>Blood</i> , 2020, 136, 43-45.	1.4	10
252	Diminished Expression of the T Cell Receptor on the Expanded Lymphocyte Population in Mrl/Mp-1pr/1pr Mice. <i>Autoimmunity</i> , 1989, 2, 97-111.	2.6	9

#	ARTICLE	IF	CITATIONS
253	MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). <i>International Immunology</i> , 2004, 16, 895-904.	4.0	9
254	Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. <i>JCI Insight</i> , 2019, 4, .	5.0	8
255	Antigen receptors of Thy-1 + dendritic epidermal cells: Implications for thymic differentiation. <i>Immunologic Research</i> , 1988, 7, 292-302.	2.9	7
256	Characterization of env gene recombination in X-ray-induced thymomas of C57BL/6 mice. <i>Molecular Carcinogenesis</i> , 1989, 2, 126-130.	2.7	6
257	Nucleotide and deduced amino acid sequence of a murine cDNA clone encoding one member of the hsp65 multigene family. <i>Nucleic Acids Research</i> , 1990, 18, 7153-7153.	14.5	6
258	Cutting Edge: Chronic Inflammatory Liver Disease in Mice Expressing a CD28-Specific Ligand. <i>Journal of Immunology</i> , 2013, 190, 526-530.	0.8	6
259	Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer. <i>PLoS ONE</i> , 2012, 7, e35222.	2.5	5
260	Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity. <i>Journal of Immunology</i> , 2017, 199, 974-981.	0.8	5
261	Nobels: Toll pioneers deserve recognition. <i>Nature</i> , 2011, 479, 178-178.	27.8	4
262	Response to Comment on "Expression of Helios in Peripherally Induced Foxp3+ Regulatory T Cells". <i>Journal of Immunology</i> , 2012, 189, 500.2-501.	0.8	3
263	Training Procedures and Task Difficulty in Brightness and Position Discriminations by Rats. <i>Psychological Reports</i> , 1972, 31, 71-76.	1.7	2
264	Expression of Ly-1 and Ly-2 on a spontaneous AKR B-cell lymphoma. <i>Immunogenetics</i> , 1983, 17, 655-659.	2.4	2
265	Lymphocyte activation and effector functions How signals are integrated in the immune system. <i>Current Opinion in Immunology</i> , 1997, 9, 293-295.	5.5	2
266	Checkpoint Blockade + Chemotherapy: the Right Combination for AML?. <i>Blood Cancer Discovery</i> , 2021, 2, 551-554.	5.0	2
267	Immune Co-signaling to Treat Cancer. , 2013, , 211-280.		1
268	Durable Responses with Ipilimumab Plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. <i>Blood</i> , 2018, 132, 4585-4585.	1.4	1
269	Structural Differences in Envelope Glycoproteins Associated with Rat Leukaemia Virus Produced by Novikoff Hepatocellular Carcinoma and Spontaneously Transformed Wistar Rat Embryo Cells. <i>Journal of General Virology</i> , 1984, 65, 743-760.	2.9	0
270	The congenic mutant B6.C-H-2bm <sup>1</sup> (H-2bm <sup>1</sup> ) serological response to the T-cell receptor on EL4. <i>Cellular Immunology</i> , 1986, 101, 586-592.	3.0	0

#	ARTICLE	IF	CITATIONS
271	Lloyd J. Old (1933–2011). <i>Science</i> , 2012, 335, 49-49.	12.6	0
272	Fc Gamma R. , 2017, , 209-228.		0
273	Protein Localization in Negative Signaling. , 2003, , 355-359.		0
274	Checkpoint Blockade and Combinatorial Immunotherapies. , 2007, , 363-390.		0
275	Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy. <i>Blood</i> , 2020, 136, 29-31.	1.4	0